Advertisement

Topics

Latest "Standard & Poor’s" News Stories

19:41 EDT 22nd October 2018 | BioPortfolio

Here are the most relevant search results for "Standard & Poor’s" found in our extensive news archives from over 250 global news sources.

More Information about Standard & Poor’s on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Standard & Poor’s for you to read. Along with our medical data and news we also list Standard & Poor’s Clinical Trials, which are updated daily. BioPortfolio also has a large database of Standard & Poor’s Companies for you to search.

Showing "Standard Poor" News Articles 1–25 of 3,600+

Monday 22nd October 2018

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care


HealthStream Announces Third Quarter 2018 Results

HealthStream, Inc. (NASDAQ: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, announced today results for the third quarter ended September 30, 2018. In the following bullet-point highlights, (i) all results are from continuing operations only (i.e., 2017 and 2018 results exclude the gain on the sale of our divested...

Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain

Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near the spine Purdue Pharma L.P. and SpineThera, Inc. today announced that the companies have entered into an agreement that provides Purdue the exclusive option to acquire SpineThera, Inc. and gain worldwide righ...


AngelMD Portfolio Company Raydiant Oximetry Awarded FDA Breakthrough Device Status

The accelerated path to approval through the breakthrough device program will enable better care to millions of mothers and babies during childbirth. SEATTLE (PRWEB) October 22, 2018 In the United States, roughly one out of every three babies born in the United States are delivered via cesarean section. According to key stakeholders, nearly half of these c-section deliveries are medically unneces...

ESMO 2018: Immunotherapy improves survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasised, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich. The current standard...

Western Dental Offers Tips on How to Choose the Proper Halloween Candy

Halloween is arriving soon. It's a fun-filled holiday that children really enjoy, especially after going around their neighborhood trick-or-treating, then arriving home to cherish their large assortment of candy. But dental practitioners aren’t nearly as enamored with Halloween, because they know the possible ramifications of eating candy. It ca...

Report: BP higher in those with poor oral health

Good oral health—in particular a lack of periodontal disease—has been linked to lower systolic blood pressure and a better chance at successful antihypertensive therapy in patients with high BP, according to research published Oct. 22 in Hypertension.

Resilinc Unveils Streamlined AI Powered EventWatch® as an Entry Level Solution for Supply Chain Risk Management

Resilinc has upgraded its EventWatch news monitoring service to give users more comprehensive and actionable intelligence on global events that could disrupt their supply chains. The company is also offering a new streamlined version of the software tailored for cost-effective use by small- to medium-sized companies. SAN FRANCISCO (PRWEB) October 22, 2018 Resilinc, the leading provider of supply ...

Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer

Survival Benefit Observed with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 with CPS=20 and CPS=1 and in Total Patient Population for KEYTRUDA in Combination with Chemotherapy KEY...

Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer

Survival Benefit Observed with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 with CPS≥20 and CPS≥1 and in Total Patient Population for KEYTRUDA in Combination with Chemotherapy KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit as First-Line Therapy for Head and Neck Cancer that has Recurred or Metas...

Caliburn, New Jersey’s Supercomputer, Catalyzes Cutting-Edge Research

NewsCaliburn, a supercomputer with the computational power of more than 10,000 standard desktop computers, is catalyzing diverse, innovative research.

Study Shows Coaching Helps People with Diabetes, Hypertension and High Cholesterol Improve Medication Adherence

Telephonic coaching helps patients take their medication more regularly; study reveals barriers to adherence Health Dialog, a leading provider of integrated population health management solutions for health plans, risk-bearing providers and self-insured employers, will release data showing its telephonic health coaching program helped patients managing...

Maintenance treatment is typically used after a standard of care treatment. It may be used throughout the patient journey with a number of different aims. #SciencefromAtoZ #ESMO18pic.twitter.com/RIKsh7jXiO

Maintenance treatment is typically used after a standard of care treatment. It may be used throughout the patient journey with a number of different aims. #SciencefromAtoZ #ESMO18 pic.twitter.com/RIKsh7jXiO

Myoscience Announces Commercial Release of Nerve Stim Enabled iovera° Smart Tip

Myoscience, Inc. announced today the commercial release of their Nerve Stim Enabled Smart Tip 1x90mm, the latest innovative addition to Myoscience’s iovera° system. Fremont, Calif. (PRWEB) October 22, 2018 Myoscience Announces Commercial Release of Nerve Stim Enabled iovera° Smart Tip New Smart Tip will be on display at 2018 Annual Assembly of AAPM&R Society in Orlando FREMONT, CA...

Verifone Introduces the First PCI-Compliant Full Touchscreen Feature for the Blind and Visually Impaired

The Royal National Institute of Blind People (RNIB), one of the UK’s leading sight loss charities, certifies Verifone’s Navigator Verifone today announced the introduction of Navigator, the first-of-its-kind payment feature with a fully integrated touchscreen to earn certification for accessibility and usability by the Royal National Institute of B...

IVT Remains the Basis and Mainstay of Revascularizing Therapy

Do we need IVT before EVT? In this commentary, the authors maintain that IVT before EVT remains the standard of care for acute stroke, regardless of arguments to the contrary. Stroke

BioClin Therapeutics to Participate in BTIG Biotech Conference

BioClin Therapeutics, Inc., a privately-held clinical stage drug development company, today announced its participation in the BTIG Biotech Conference taking place at the Langham Hotel in New York. Dr. Graeme Currie, Ph.D., Chief Operating Officer, will participate in a panel “Targeted Oncology Therapies – Material Advancements, Intriguing Pot...

Breast Cancer Trial: First-Line Chemo-Immuno Combo Improves Outcomes

A large Phase III trial, the Impassion130 trial, has produced results supporting the use of chemotherapy plus immunotherapy as first-line treatment in certain patients with triple-negative breast cancer. The trial evaluated the combination of nab-paclitaxel, which is a chemotherapy drug, and atezolizumab, which is a checkpoint inhibitor. Together, the chemotherapeutic and the checkpoint inhibitor ...

AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018

35 scientific data presentations and publications, including new evidence for LOKELMA™ (sodium zirconium cyclosilicate) in hyperkalemia and FARXIGA® (dapagliflozin) on renal endpoints in type-1 diabetes Latest data on potential new medicine roxadustat for anemia in chronic kidney disease and early-stage findings from multiple investigati...

Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma

– Combination of cabozantinib and atezolizumab is well tolerated and shows promising anti-tumor activity – – Safety and efficacy data support 18 expansion cohorts evaluating the combination in 12 different tumor types – Exelixis, Inc. (NASDAQ:EXEL) today announced results from the dose-escalation stage of the phase 1b COSMIC-021...

Vizient, Inc. Recognized as a “Best Places to Work in Healthcare in 2018” by Modern Healthcare

Vizient, Inc. announces it has been ranked in the top 50 among healthcare suppliers/vendors in the Modern Healthcare 2018 Best Places to Work in Healthcare list.

MetLife Foundation and Verb Announce Winner of Financial Innovation Competition

Onward Financial receives $100,000 grant to expand full-service employee financial wellness program SOURCE: MetLife Inc. DESCRIPTION:NEW YORK, October 22, 2018 /3BL Media/ – MetLife Foundation and Verb announced Onward Financial as the first place winner of the Inclusion Plus competition in the United States. The competition was open to entrepreneurs, non-profits and other social impact organ...

Feedback expands its European customer base with new orders for TexRAD® from prestigious European university hospitals

Cambridge, 22 October 2018: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company, Feedback Medical Ltd, has received a number of substantial orders for TexRAD®, its patented image texture analysis technology, from prestigious university hospitals across Europe. The orders have come...

MOLOGEN presented final results from the randomized phase II IMPULSE study at ESMO 2018

DGAP-News: MOLOGEN AG / Key word(s): Conference 22.10.2018 / 09:24 The issuer is solely responsible for the content of this announcement. PRESS RELEASE N 23/2018 of 22 October 2018 MOLOGEN presented final results from the randomized phase II IMPULSE study at ESMO 2018 Berlin, 22 October 2018 - The biopharmaceutical company MOLOGEN AG presented final data from the exploratory phase II ...

Waking Up To The Sleep Crisis: Improving Your Well-being Could Be Easier Than You Think

Regardless of the benefits sleep gives us we’re still not doing it. The Great British Bedtime Report suggesting that almost a third of us are still getting poor sleep most nights, and that stress and worry remain in the top three reasons why. This is not just for those in high profile positions.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks